Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

Abstract Gain of chromosome 1q (+ 1q) is commonly identified in multiple myeloma and has
been associated with inferior outcomes. However, the prognostic implication of+ 1q has not …

Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …

While there is extensive evidence for genetic variation as a basis for treatment resistance,
other sources of variation result from cellular plasticity. Using multiple myeloma as an …

Dysregulation of polycomb repressive complex 2 (PRC2) promotes oncogenesis partly
through its enzymatic function for inducing trimethylation of histone H3 lysine 27 …

Multiple myeloma is a clonal disease of long-lived plasma cells and is the second most
common hematological cancer behind Non-Hodgkin's Lymphoma. Malignant transformation …

Simple Summary Multiple myeloma is an incurable blood cancer caused by the malignant
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …

Immunomodulatory drugs (IMiD) are a backbone therapy for multiple myeloma (MM).
Despite their efficacy, most patients develop resistance, and the mechanisms are not fully …

Monoclonal gammopathy of undetermined significance (MGUS) is of considerable clinical
importance to primary care physicians given its high prevalence in the general population …